Neonatal sepsis in alloimmune hemolytic disease of the fetus and newborn: A retrospective cohort study of 260 neonates.
central-line
hemolytic disease of the newborn
neonates
sepsis
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
30
09
2022
received:
02
08
2022
accepted:
13
10
2022
pubmed:
6
11
2022
medline:
18
1
2023
entrez:
5
11
2022
Statut:
ppublish
Résumé
Among neonates with hemolytic disease of the fetus and newborn (HDFN), we aimed to describe the frequency of central-line use, indications for insertion, and incidence of confirmed and suspected sepsis, including antibiotic treatment over a 10-year surveillance period. All neonates with HDFN admitted to our neonatal intensive care unit between January 2012 and December 2021 were included in this retrospective, cohort study. Annual proportions of infants with a central-line and central-line-associated bloodstream infection (CLABSI) rates (per 1000 central-line days and per 100 infants) were evaluated. Numbers of confirmed and suspected early- and late-onset sepsis episodes were assessed over the entire study period. Of the 260 included infants, 25 (9.6%) were evaluated for suspected sepsis, with 16 (6.2%) having ≥1 confirmed sepsis episode. A total of 123 central-lines were placed in 98 (37.7%) neonates, with impending exchange transfusion (ET) being the most frequent indication. Of the 34 (34.7%) neonates in whom a central-line was placed due to impending ET, 11 (32.4%) received no ET. Overall CLABSI incidence was 13.58 per 1000 central-line days. Neonates with a central-line had a higher risk for confirmed late-onset infection (RR 1.11, 95% CI: 1.04-1.20) and sepsis work-up (RR 1.10, 95% CI: 1.03-1.17) compared to infants without a central-line. Sepsis incidence among neonates with HDFN remains high, in particular in those with a central-line. Considering the substantial proportion of neonates with a central-line without eventual ET, central-line placement should be delayed until the likelihood of ET is high.
Sections du résumé
BACKGROUND
Among neonates with hemolytic disease of the fetus and newborn (HDFN), we aimed to describe the frequency of central-line use, indications for insertion, and incidence of confirmed and suspected sepsis, including antibiotic treatment over a 10-year surveillance period.
STUDY DESIGN AND METHODS
All neonates with HDFN admitted to our neonatal intensive care unit between January 2012 and December 2021 were included in this retrospective, cohort study. Annual proportions of infants with a central-line and central-line-associated bloodstream infection (CLABSI) rates (per 1000 central-line days and per 100 infants) were evaluated. Numbers of confirmed and suspected early- and late-onset sepsis episodes were assessed over the entire study period.
RESULTS
Of the 260 included infants, 25 (9.6%) were evaluated for suspected sepsis, with 16 (6.2%) having ≥1 confirmed sepsis episode. A total of 123 central-lines were placed in 98 (37.7%) neonates, with impending exchange transfusion (ET) being the most frequent indication. Of the 34 (34.7%) neonates in whom a central-line was placed due to impending ET, 11 (32.4%) received no ET. Overall CLABSI incidence was 13.58 per 1000 central-line days. Neonates with a central-line had a higher risk for confirmed late-onset infection (RR 1.11, 95% CI: 1.04-1.20) and sepsis work-up (RR 1.10, 95% CI: 1.03-1.17) compared to infants without a central-line.
CONCLUSIONS
Sepsis incidence among neonates with HDFN remains high, in particular in those with a central-line. Considering the substantial proportion of neonates with a central-line without eventual ET, central-line placement should be delayed until the likelihood of ET is high.
Identifiants
pubmed: 36334304
doi: 10.1111/trf.17176
pmc: PMC10099948
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-124Informations de copyright
© 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Expert Rev Hematol. 2017 Jul;10(7):607-616
pubmed: 28503958
Pediatrics. 2004 Aug;114(2):348-55
pubmed: 15286215
Vox Sang. 2020 Feb;115(2):196-201
pubmed: 31858620
PLoS One. 2020 Jul 20;15(7):e0235807
pubmed: 32687543
Turk J Pediatr. 2010 Jul-Aug;52(4):367-71
pubmed: 21043381
Pediatr Infect Dis J. 2009 Dec;28(12):1052-6
pubmed: 19953725
Vox Sang. 2010 Jul 1;99(1):65-70
pubmed: 20331535
J Pediatr. 2004 May;144(5):626-31
pubmed: 15126997
BMC Pediatr. 2005 Jul 08;5:22
pubmed: 16004613
Pediatrics. 2007 Jul;120(1):27-32
pubmed: 17606558
Ann Surg. 1978 Jan;187(1):1-7
pubmed: 413500
Neonatology. 2013;103(2):141-7
pubmed: 23235106
Neonatology. 2012;101(4):306-10
pubmed: 22354012
Antimicrob Resist Infect Control. 2021 Feb 5;10(1):31
pubmed: 33546759
Transfusion. 2023 Jan;63(1):117-124
pubmed: 36334304
Semin Fetal Neonatal Med. 2015 Feb;20(1):52-57
pubmed: 25585889
Front Pediatr. 2017 Jun 20;5:142
pubmed: 28676849
Am J Infect Control. 2013 Dec;41(12):1148-66
pubmed: 24274911
Vox Sang. 2012 Apr;102(3):228-33
pubmed: 21923860
Vox Sang. 2021 Oct;116(9):990-997
pubmed: 33730387
Hematology Am Soc Hematol Educ Program. 2015;2015:146-51
pubmed: 26637714
Pediatrics. 2004 Jul;114(1):297-316
pubmed: 15231951
Am J Obstet Gynecol. 2012 Feb;206(2):141.e1-8
pubmed: 22030316
Am J Obstet Gynecol. 2001 Apr;184(5):1015-20
pubmed: 11303214